DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped ...

Danaher’s fair value estimate has been trimmed slightly from US$250.14 per share to US$247.83 per share, a small move that still matters if you are tracking entry points and valuation discipline. That ...

Is DHR a good stock to buy? We came across a bullish thesis on Danaher Corporation on r/ValueInvesting by One_Complaint_2945.

By Jonathan Stempel April 23 (Reuters) - Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and life-sciences company of defrauding them by overstating demand ...

To be sure, Danaher is not actually a biotech company. It sells tools, instruments, and services used by biotech and pharma companies to develop and manufacture drugs. It's essentially a ...

Shares of Danaher popped more than 6% on Tuesday after the life sciences company delivered a strong quarter and reaffirmed its guidance — signaling the longtime Club stock is back on track. Revenue ...

If you are wondering whether Danaher's current share price reflects its underlying worth, the recent performance gives plenty ...

We recently upgraded our economic moat rating for Danaher DHR to wide from narrow. An acquisition-focused strategy has helped the company become a key player in scientific instruments and consumables ...

Danaher Corporation (DHR) has agreed to pay $172.5M to settle a class action lawsuit filed by a group of investors who accused the company of misrepresenting demand for its test and vaccine equipment ...

New pilot program targets a flue-gas pre-treatment bottleneck that affects carbon capture reliability, cost, and scalability Supported by $1 million CAD in funding from Emissions Reduction Alberta ...

View Danaher Corporation DHR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Feb 17 (Reuters) - Danaher, ⁠a $150 ⁠billion U.S. company that makes ⁠tools used in developing and testing medicines, on Tuesday agreed to buy Masimo for $9.9 billion, expanding in patient-monitoring ...